Vanguard Group Reduces $55M in Arrowhead Pharmaceuticals, Inc. ($ARWR)

Vanguard Group recently trimmed its holdings in Arrowhead Pharmaceuticals, Inc. (NasdaqGS: ARWR). According to its latest 13F filing with the SEC, Vanguard reduced its position by 742,749 shares, bringing its total to 15,293,121 shares. The position is valued at approximately $1.14 billion as of the filing date.

What Changed in Vanguard Group's Arrowhead Pharmaceuticals Position

Vanguard Group's decision to cut its stake in Arrowhead Pharmaceuticals by 4.63% reflects a reduction from 16,035,870 shares to 15,293,121 shares. This adjustment represents a decrease of 742,749 shares, with the total position valued at around $1.14 billion.

Other Institutional Activity in Arrowhead Pharmaceuticals

In the same period, BlackRock, Inc. reduced its holdings by 3,157,063 shares, ending with 18,161,519 shares worth about $1.14 billion. A different approach was seen from Avaro Capital Advisors LLC, which increased its stake by 74,999 shares, reaching a total of 10,699,999 shares valued at roughly $670.9 million. Meanwhile, FMR LLC boosted its position by 746,244 shares, holding 7,266,652 shares valued at approximately $455.6 million. State Street Corp also added 92,300 shares, bringing its total to 6,496,130 shares worth about $407.3 million.

Arrowhead Pharmaceuticals Stock Snapshot

Shares of Arrowhead Pharmaceuticals are trading at $74.52. The company, with a market cap of approximately $10.5 billion, has a forward P/E ratio of -17.17, indicating it's not currently profitable. The stock's beta is 1.275, reflecting its volatility relative to the market. Arrowhead has seen a 52-week low of $14.30 and a high of $82.26. Its 50-day moving average is $72.76, while the 200-day moving average is $56.99. The company maintains a strong current ratio of 6.23 and a high debt-to-equity ratio of 231.05.

Recent Earnings

Arrowhead Pharmaceuticals reported revenue of $622 million, although it experienced a revenue decline of 86.4%. The net margin is negative at -48.38%, and the return on equity is -42.37%, indicating financial challenges. The company is expected to announce its next earnings on May 7, 2026.

Insider Buying and Selling at Arrowhead Pharmaceuticals, Inc.

Recent insider transactions include planned sales by Hongbo Lu, who sold 2,970 shares on May 12, 2026, at an average price of $76.88. Chief Medical Officer James Hamilton sold 10,000 shares on April 23, 2026, at $75.00 under a planned transaction. CFO Daniel Joseph Apel also sold 13,095 shares at $71.35 on April 22, 2026, in a planned sale. Notably, COO Patrick O'Brien bought 75,000 shares on January 6, 2026.

Analysts Set New Price Targets

Analyst activity included Bernstein maintaining a hold rating with a $46.00 target on May 13, 2026. RBC Capital maintained a buy rating with an $87.00 target on May 8, 2026, while JP Morgan initiated coverage with a buy rating and an $88.00 target on May 1, 2026. The consensus among analysts is a buy rating, with a target mean price of $88.17, based on 12 analyst opinions.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. is a biotechnology company based in Pasadena, California. It specializes in developing medicines for intractable diseases. Its pipeline includes treatments in various stages of clinical trials, focusing on reducing the production of specific proteins and genes linked to diseases. The company collaborates with major pharmaceutical firms like GlaxoSmithKline, Takeda, Amgen, and Sarepta Therapeutics. Arrowhead was founded in 2003 and is led by CEO Dr. Christopher R. Anzalone.

Bottom Line

Vanguard Group's decision to reduce its stake in Arrowhead Pharmaceuticals is part of the fund's regular portfolio adjustments. While the 13F filing provides a glimpse into past holdings, it may not reflect Vanguard's current position. Investors often track such filings to gauge institutional sentiment and potential market movements.